Bifogade filer
PDF
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
AcouSort's collaboration with a global life science company has reached a significant milestone with the delivery of a fully functional test system for cell therapy processing. The system is operating according to the partnering company's requirements with the intention of being integrated into a new automated cell therapy production system.
The order for the prototype was communicated in July 2023, and the unit has now been successfully delivered to the partnering company. During the installation, several researchers from the partnering company were trained on the prototype to ensure efficient execution of the evaluation phase. During this period, product design activities investigating a potential integration into their new cell therapy production system will also be performed.
Over the coming months, AcouSort will continue discussions with the partnering company to define the next steps of the collaboration. The continued collaboration constitutes a very important step towards the development of OEM components to the partnering company's future cell therapy products and instruments.
The order for the prototype is a clear verification of the commercial potential of AcouSort's focus on developing OEM modules for cell therapy solutions in clinical settings.
"The collaboration with the partnering company is a perfect example of our research-to-OEM strategy. By delivering a complete test system, we have taken a significant step towards our ultimate goal of securing an OEM deal with this customer. We will follow the customer's evaluation process very closely and offer all the support they may need," says Torsten Freltoft, AcouSort's CEO.